药康生物(688046) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 157,087,264.43, representing an increase of 11.96% compared to the same period last year[5] - The net profit attributable to shareholders decreased by 5.06% to CNY 29,479,404.17[5] - The net profit excluding non-recurring gains and losses was CNY 22,868,086.62, showing a slight increase of 2.74%[6] - The basic and diluted earnings per share were both CNY 0.07, reflecting a decrease of 12.50%[6] - Total operating revenue for Q1 2024 reached ¥157,087,264.43, an increase of 11.5% compared to ¥140,304,915.96 in Q1 2023[22] - Net profit for Q1 2024 was ¥29,479,404.17, a decrease of 5.1% from ¥31,050,205.03 in Q1 2023[23] - Basic and diluted earnings per share for Q1 2024 were both ¥0.07, down from ¥0.08 in Q1 2023[24] Research and Development - The total R&D investment amounted to CNY 23,002,751.52, which is a decrease of 5.07% year-on-year, accounting for 14.64% of operating revenue, down by 2.63 percentage points[6] - Research and development expenses for Q1 2024 were ¥23,002,751.52, slightly down from ¥24,232,493.78 in Q1 2023[23] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,559,431,497.50, a decrease of 0.70% from the end of the previous year[6] - As of March 31, 2024, total assets amounted to RMB 2,559,431,497.50, a decrease from RMB 2,577,589,878.58 as of December 31, 2023, reflecting a decline of approximately 0.7%[16] - Total current liabilities decreased to RMB 340,772,915.39 from RMB 366,409,071.83, representing a reduction of about 6.9%[18] - The company reported a total non-current asset value of RMB 911,323,787.90, down from RMB 920,066,986.97, a decrease of approximately 1.6%[17] Cash Flow - Cash flow from operating activities in Q1 2024 was -¥52,604,737.13, compared to -¥14,154,229.37 in Q1 2023, indicating a worsening cash flow situation[27] - Cash inflow from investment activities totaled $713,753,844.52, an increase from $434,308,686.92 in the previous period, reflecting strong investment returns[28] - Cash outflow from investment activities was $643,359,140.59, compared to $413,626,953.96 previously, indicating increased investment expenditures[28] - Net cash flow from investment activities was $70,394,703.93, up from $20,681,732.96, showing improved investment performance[28] - Cash inflow from financing activities amounted to $19,950,000.00, slightly down from $21,000,000.00 in the prior period[28] - Cash outflow from financing activities increased to $35,994,111.73 from $1,693,266.28, indicating higher debt repayments and distributions[28] - Net cash flow from financing activities was -$16,044,111.73, a decline from $19,306,733.72, reflecting a shift in financing strategy[28] - The ending balance of cash and cash equivalents was $561,598,014.01, up from $447,070,730.89, demonstrating a solid liquidity position[29] - The company reported a net increase in cash and cash equivalents of $1,604,800.86, a significant decrease from $25,477,976.76 in the previous period[28] - The impact of exchange rate fluctuations on cash and cash equivalents was -$141,054.21, compared to -$356,260.55 previously, indicating reduced currency risk[28] Shareholder Information - Shareholders' equity attributable to the parent company increased by 0.31% to CNY 2,131,228,008.17[6] - The total number of ordinary shareholders at the end of the reporting period was 8,007[11] - The company's equity attributable to shareholders reached ¥2,131,228,008.17, up from ¥2,124,656,444.32 in the previous quarter[19] - Other comprehensive income attributable to shareholders was ¥74,046.00 in Q1 2024, recovering from a loss of -¥176,070.19 in Q1 2023[24] Government and Financial Activities - The company received government subsidies amounting to CNY 2,463,890.59, which are not related to normal business operations[8] - The fair value changes of financial assets and liabilities resulted in a gain of CNY 5,316,982.12[8] - The company has engaged in share lending activities, with 300,000 shares lent out through the securities lending program[14] - The company continues to focus on expanding its market presence and enhancing its product offerings, although specific new products or technologies were not detailed in the report[14] Operating Costs - Operating costs for Q1 2024 were ¥53,421,017.57, up from ¥43,072,255.75 in Q1 2023, reflecting a 24.5% increase[22] - Sales expenses increased to ¥22,298,328.56 in Q1 2024 from ¥18,071,131.99 in Q1 2023, marking a 23.5% rise[23] Accounting Standards - The company is not applying new accounting standards for the current financial year, maintaining consistency in financial reporting[29]